No content found

Sunday, January 30 | 4:00PM - 8:00PM
Registration
Arrival and Registration
Room: Longs Peak Foyer


Sunday, January 30 | 6:00PM - 8:00PM
Welcome Mixer

Room: Longs Peak Foyer
No registration fees are used to fund alcohol served at this function.

Monday, January 31 | 7:00AM - 8:00AM
Breakfast

Room: Quandary Peak


Monday, January 31 | 8:00AM - 9:00AM
Keynote Address
Welcome and Keynote Address
Room: Grays Peak


David Baker, University of Washington, USA
De novo Design of Function

Monday, January 31 | 9:00AM - 11:15AM
Plenary AM
Computational de novo Design of Biomolecules
Room: Grays Peak


Jane S. Richardson, Duke University, USA
A Brief History of Protein Design

Coffee Break

Stephen L. Mayo, Caltech, USA
Computational Design of Novel Antibody Small Molecule Conjugates

Tanja Kortemme, University of California, San Francisco, USA
Computational Design of New Molecular Geometries and Ligand-Controlled Functions

Anastassia A. Vorobieva, VIB-VUB, Belgium
Short Talk: De Novo Design of Pore-Forming Transmembrane beta-barrels

Alexandra K. Van Hall-Beauvais, École polytechnique fédérale de Lausanne, Switzerland
Short Talk: De Novo Design of Site-specific Protein Binders Using Learned Surface Fingerprints

Anum Glasgow, Columbia University, USA
Short Talk: Biophysical Requirements for Affinity and Stability in Engineered Anti-SARS-CoV-2 Receptor Traps

Monday, January 31 | 9:00AM - 11:15AM
Plenary AM
Therapeutic Antibodies from Patients
This session is from Antibodies as Drugs
Room: Longs Peak


Adrian C. Hayday, King's College London School of Medicine, UK
Anti-Cytokine Abs from Autoimmune Patients

Coffee Break

Stephen Quake, Stanford University, USA
Isolation of Rare Human Plasma Cells: Showcasing Anti-Peanut IgE Antibodies

Natalia Freund, Tel Aviv University, Israel
Human-Isolated Antibodies Targeting Mycobacterium Tuberculosis

Kelsey Pilewski, Vanderbilt University, USA
Short Talk: Functional HIV-1/HCV Cross-reactive Antibodies Isolated from a Chronically Co-infected Donor

† Matteo Broketa, Institut Pasteur, France
Short Talk: High throughput Affinity Repertoire Mapping of Plasmablasts against SARS-COV2 RBD and Variants following mRNA Vaccination of Naïve and COVID-19-Convalescent Individuals

Jarrod J. Mousa, University of Georgia, USA
Short Talk: Broadly Reactive Anti-Pneumococcal Antibodies for Disease Treatment


Monday, January 31 | 11:15AM - 5:00PM
On Own for Lunch



Monday, January 31 | 11:15AM - 1:00PM
Poster Setup

Room: Quandary Peak


Monday, January 31 | 1:00PM - 10:00PM
Poster Viewing

Room: Quandary Peak


Monday, January 31 | 2:30PM - 4:30PM
Workshop
Workshop
This session is from Antibodies as Drugs
Room: Longs Peak


Xiaoying Yu, The Scripps Research Institute, USA
Asymmetric and Non-Stoichiometric Recognition Results in Broad Protection Against Ebolaviruses by a Two-Antibody Cocktail

Franziska Heckel, University of Southampton, UK
CD27 Antibody Mediated Agonism is Facilitated through Epitope-Dependent Receptor Clustering and can be Augmented through Fc-Engineering

Linya Wang, Twist Bioscience, USA
Functional ADORA2A Antibodies Demonstrate Antagonistic and Tumor Suppression Activities

Fergus R. Byrne, Boehringer Ingelheim, USA
An Anti Human LAIR-1 Agonistic Monoclonal Antibody Requires Fc Receptor Engagement for Functional Efficacy

Jiachen Huang, University of Georgia, USA
Therapeutic Monoclonal Antibodies for Human Metapneumovirus

Daniel Leventhal, Generate Biomedicines, USA
Computational Directed Improvements in Developability and Immunogenicity for Therapeutic Antibodies

Taylor Engdahl, Vanderbilt University Medical Center, USA
Broadly Neutralizing Hantavirus Antibodies Target an Antigenic Site Spanning the Gn/Gc Heterodimer


Monday, January 31 | 4:30PM - 5:00PM
Coffee Available

Room: Longs Peak Foyer


Monday, January 31 | 5:00PM - 7:00PM
Plenary PM
Repurposing Proteins for Binding and Catalysis
Room: Grays Peak


William F. DeGrado, University of California, San Francisco, USA
de novo Design of Binding Proteins and Catalysts

Birte Höcker, University of Bayreuth, Germany
Evolution and Design of Proteins

Dek Woolfson, University of Bristol, UK
Exploring the Dark Space of Protein Structure and Function through Rational and Computational Design

Neil P. King, University of Washington, USA
Computational Design of Self-Assembling Protein Nanomaterials for Medical Applications

Pranam Chatterjee, MIT Media Lab, USA
Short Talk: De Novo Design of Potent Anti-CRISPR Proteins

Rodney Park, University of North Carolina at Chapel Hill, USA
Short Talk: Improving Enzymatic Efficiency by more than 1000-Fold through Computational Interface Design of a Substrate Recruitment Domain

Monday, January 31 | 5:00PM - 7:00PM
Plenary PM
Antibodies from Within: Vaccination and Delivery Technologies
This session is from Antibodies as Drugs

Room: Longs Peak


Matthieu Mahévas, Institut Necker Enfants Malades, INSERM, France
Maturation of Memory B cells after SARS-CoV2 Infection and mRNA Vaccine

Peter D. Kwong, NIAID, National Institutes of Health, USA
Anti-HIV and Anti-Malarial Antibodies Elicited by Vaccination

Coffee Break

Andrea Carfi, Moderna, USA
Antibody-Inducing mRNA-Based Vaccine for COVID-19: 1 Year Experience in Humans

Ronald C. Desrosiers, University of Miami Miller School of Medicine, USA
AAV Delivery of Antibodies for Long-Term Protection

Tineke Cantaert, Institut Pasteur Cambodia, Cambodia
Human Anti-Dengue Antibody Responses

Blake M. Hauser, Harvard Medical School, USA
Short Talk: Rationally Designed Immunogens Enable Immune Focusing Following SARS-CoV-2 Spike Imprinting

Elaine C. Chen, Vanderbilt University, USA
Short Talk: Systematic Analysis of the Private and Public Ebola Specific Antibody Response


Monday, January 31 | 7:00PM - 8:00PM
Social Hour with Lite Bites

Room: Quandary Peak
No registration fees are used to fund alcohol served at this function.

Monday, January 31 | 7:30PM - 10:00PM
Posters
Poster Session 1
Room: Quandary Peak


Tuesday, February 01 | 7:00AM - 8:00AM
Breakfast

Room: Quandary Peak


Tuesday, February 01 | 8:00AM - 11:00AM
Plenary AM
Energy Landscape Search for Affinity and Specificity
Room: Grays Peak


Amy E. Keating, Massachusetts Institute of Technology, USA
Mapping Peptide Binding Specificity Space

Roberto A. Chica, University of Ottawa, Canada
Computational Design of Protein Energy Landscapes

Coffee Break

Bruce Donald, Duke University, USA
Algorithms for Ensemble-Based Computational Protein Design

Sophie Barbe, Université de Toulouse, France
Search Algorithms in Protein Design

Jilliane Bruffey, University of Washington, USA
Short Talk: Design of Conditionally Active Proteins for the Treatment of Solid Tumors

† Nick Wells, Wesleyan University, USA
Short Talk: Computational Design of Allosterically Acting Mutations using MD Simulations and Rosetta

Clara Tabea Schoeder, Leipzig University Medical Faculty, Germany
Short Talk: Structure-Based Immunogen Design to Target Ebola and Marburg Virus Glycoprotein Epitopes

Tuesday, February 01 | 8:00AM - 11:00AM
Plenary AM
New Targets and Tools
This session is from Antibodies as Drugs
Room: Longs Peak


David P. Humphreys, UCB Pharma, UK
IgG FcRn Blockade Therapeutics

Esther Breij, Genmab, Netherlands
Enhanced IgG Hexamerization for Increased Therapeutic Antibody Potency

Amita Datta-Mannan, Eli Lilly & Company, USA
FcRn Binding Ab Mutants, Peptide Fusions and Glycan Effects

Pierre Bruhns, Institut Pasteur, France
Human Autoimmune Plasma Cell Repertoires

Stefan Gerhardy, Genentech, USA
Short Talk: Allosteric Inhibition of HtrA1 Activity by a Conformational 'Lock' Mechanism to Treat Age-related Macular Degeneration

Andrea Shiakolas, Vanderbilt University, USA
Short Talk: Rapid and Efficient Discovery of Potently Neutralizing SARS-CoV-2 Antibodies Using LIBRA-seq with Ligand Blocking


Tuesday, February 01 | 11:00AM - 5:00PM
On Own for Lunch



Tuesday, February 01 | 11:00AM - 1:00PM
Poster Setup

Room: Quandary Peak


Tuesday, February 01 | 1:00PM - 10:00PM
Poster Viewing

Room: Quandary Peak


Tuesday, February 01 | 4:30PM - 5:00PM
Coffee Available

Room: Longs Peak Foyer


Tuesday, February 01 | 5:00PM - 7:00PM
Plenary PM
Prediction and Design of Protein Ligand Interactions
Room: Grays Peak


Brian K. Shoichet, University of California, San Francisco, USA
Ultra-Large Library Docking for Discovering New Chemotypes

Nir London, Weizmann Institute of Science, Israel
Designing Covalent Inhibitors

Xavier Barril, Gain Therapeutics, Spain
High-Throughput Virtual Dissociation Experiments: Application to Fragment Screening

Ora Furman, Hebrew University, Hadassah Medical School, Israel
Peptides as Far as the Eye Can See

Simon Kretschmer, University of California San Francisco, USA
Short Talk: Design of Multi-layer Protein Switches Controlled by FDA-Approved Small-Molecule Drugs

Patrick Kelly, Arizona State University, USA
Short Talk: Computational Design of a Protein-Based Fluorescent Metal Sensor

Tuesday, February 01 | 5:00PM - 7:00PM
Plenary PM
The Rise of Bispecifics
This session is from Antibodies as Drugs
Room: Longs Peak


Stefan Weigand, F. Hoffmann La Roche AG, Switzerland
Complex Biologics from Roche's Pipeline

Matthew Sleeman, Regeneron Pharmaceuticals, Inc., USA
Costimulatory Bispecifics Antibodies

Coffee Break

Mark S. Dennis, Denali Therapeutics, USA
BBB Crossing Bispecific Abs

Bruce Keyt, IGM Biosciences, USA
IgM Bispecifics and Multimers as Therapeutics

Natasa Vukovic, University of Edinburgh, UK
Short Talk: Development of Bispecific IgE Antibodies

Rony Dahan, Weizmann Institute of Science, Israel
Short Talk: Cell Type-selective Bispecific Antibodies to Separate Toxicity and Efficacy of Agonistic Antibodies


Tuesday, February 01 | 7:00PM - 8:00PM
Social Hour with Lite Bites

Room: Quandary Peak
No registration fees are used to fund alcohol served at this function.

Tuesday, February 01 | 7:30PM - 10:00PM
Posters
Poster Session 2
Room: Quandary Peak


Wednesday, February 02 | 7:00AM - 8:00AM
Breakfast

Room: Quandary Peak


Wednesday, February 02 | 8:00AM - 8:45AM
Keynote Address (JT)
Keynote Address (Joint)
Room: Grays/Longs Peaks


Charlotte Deane, University of Oxford, UK
Deep Learning based on Ab Sequences and Structure Information

Wednesday, February 02 | 8:45AM - 11:00AM
Plenary AM (JT)
Repertoires, Learning and in Silico Design (Joint)
Room: Grays/Longs Peaks


Arvind Sivasubramanian, Adimab LLC, USA
Computational Modeling and Design of Antibody Function

Coffee Break

Sai T. Reddy, ETH Zurich, Switzerland
Engineering an Antigen-Binding Protein by Deep Learning-Guided Directed Evolution

Byung-Ha Oh, Korea Advanced Institute of Science & Technology, South Korea
Short Talk: Computational Design of a Neutralizing Antibody with Pico- to Femto-Molar Binding Affinity for all SARS-CoV-2 Variants of Concern

Reda Rawi, National Institute of Allergy and Infectious Diseases, NIH, USA
Short Talk: In silico Improvement of Highly Protective Anti-malarial Antibodies

Wednesday, February 02 | 11:00AM - 5:00PM
On Own for Lunch



Wednesday, February 02 | 4:30PM - 5:00PM
Coffee Available

Room: Longs Peak Foyer


Wednesday, February 02 | 5:00PM - 6:45PM
Plenary PM
Machine Learning for Design of Enhanced Therapeutics and Biocatalysts

Room: Grays Peak


Timothy Whitehead, University of Colorado Boulder, USA
One-Shot Design and Engineering of Portable in vitro and in vivo Biosensors

Joanna Slusky, University of Kansas, USA
Machine Learning for Accelerating the Design of Metalloenzymes.

Bruno Emanuel Correia, École Polytechnique Fédérale de Lausanne, Switzerland
Deciphering Interaction Fingerprints from Protein Molecular Surfaces using Geometric Deep Learning

Daniela Grabs, Arzeda Corp, USA
Designer Enzymes to Deliver Performance Chemicals and Materials

† Possu Huang, University of California, San Francisco, USA
Short Talk: Epitope-Specific Antibody Design via Deep Learning-Based Structural Modeling

Wednesday, February 02 | 5:00PM - 6:45PM
Plenary PM
Novel Therapeutic Antibodies in the Clinic
This session is from Antibodies as Drugs
Room: Longs Peak


Cecile Geuijen, Merus NV, Netherlands
Targeting T/NK Costimulatory Receptors in Oncology (4-1BBxPD-L1 Bispecific Antibody)

Eric Vivier, Aix Marseille University and Inna Pharma, France
Exploiting NK Cells to Induce Anti-Tumor Response in Preclinical and Clinical Setting

Neil Brewis, F-star Biotechnology Ltd., UK
Immuno-Oncology Therapeutics (including OX40x4-1BB Bispecifics)

Christos Kyratsous, Regeneron Pharmaceuticals Inc, USA
Anti-Covid-19 Therapeutic mAbs: Design and Results One Year After

Tibor Keler, Celldex Therapeutics, Inc., USA
Short Talk: Development of the Antagonist KIT Antibody CDX-0159 for Mast Cell Driven Diseases


Wednesday, February 02 | 6:45PM - 7:00PM
Plenary
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Grays Peak


Wednesday, February 02 | 6:45PM - 7:00PM
Plenary
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from Antibodies as Drugs
Room: Longs Peak


Wednesday, February 02 | 7:00PM - 8:00PM
Social Hour with Lite Bites

Room: Quandary Peak
No registration fees are used to fund alcohol served at this function.

Wednesday, February 02 | 8:00PM - 9:00PM
Cash Bar

Room: Quandary Peak


Thursday, February 03 | 10:29AM - 10:29AM
Departure



*Session Chair
†Invited, not yet responded.

No content found

No content found

No content found